The OsteoMAX-XF claims to be the first fully defined, xeno-free human mesenchymal stem cell differentiation medium.
The company claims that the new formulation, licensed from Plasticell, produces more consistent and potent osteogenic differentiation than currently available formulations, enabling a more reproducible, efficient method for creating bone tissue and advancing research in bone disease and healing.
Mineralisation can be detected in less than one week, whereas competing products that contain serum require approximately 21 days to produce similar levels of bone formation.
EMD Millipore manufactures and distributes the medium globally for research purposes while Plasticell retains all rights over therapeutic applications.
Nick Asbrock, stem cell product manager at EMD Millipore, said: “This unique media formulation will help accelerate research in a wide range of bone related diseases such as osteoporosis. Researchers will now be able to derive bone tissue from MSCs in a more rapid and consistent manner.”